MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront. The deal gives MSD exclusive rights to the ...

Narrator: Ooooh, new magnet? Go on then, let’s see it in action. Ooooh. Haha, whoops! Does that mean things will be attracted to you now? Uh oh! Those forks look pointy! Hey, why aren’t those metal ...